Axsome Therapeutics, Inc. (AXSM)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Axsome Therapeutics, Inc. currently loses $5.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Axsome Therapeutics beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported November 2, 2026, with EPS of -$0.25 topping the -$0.63 estimate by $0.38 and revenue of $259.7 million topping the $249.2 million consensus (+4.2%). Revenue rose ~52% from about $171.0 million a year ago, led by Product Sales, which increased ~47% to roughly $250.0 million, while Royalty and Milestone Revenue climbed ~706% to about $9.7 million off a smaller base. Profitability stayed high at the gross line, with gross profit of roughly $241.9 million translating to a gross margin of ~93%, while operating results remained negative, with an operating margin of roughly -4% and operating income of about -$11.1 million. Net income was about -$12.9 million, improving ~73% from roughly -$47.2 million a year ago, and the EPS loss narrowed ~73% from -$0.94. Cash flow from operations was negative at about -$9.5 million. For the next period, consensus calls for EPS of -$0.06 on revenue of $286.8 million.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a Biotechnology company listed on the NASDAQ under AXSM that develops and commercializes central nervous system therapies in the United States. The company generated $638.5 million in revenue in FY2025 and focuses on prescription medicines and late-stage development candidates for neurologic and psychiatric conditions.
Today's Snapshot
The day ended with AXSM 1.4% lower at 134.00, in line with a weaker sector. Volume was about two-thirds of its usual level.
Trading Volume
Below 10d avg (941.5K)
650.5K
vs S&P 500 Today
Underperforming Market
-1.17%
Updated: November 18, 2026 at 21:13 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$138.80 - $182.46Sell
- RSI (14)35.23Neutral
- Stochastic %K (14, 3, 3)44.70Neutral
- MACD Level (12, 26)-7.86Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.